Janssen-Cilag International, a Johnson & Johnson company, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of a type II extension of indication for Rybrevant in combination with chemotherapy for the treatment of adult patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson call volume above normal and directionally bullish
- Under Armour downgraded, Snap upgraded: Wall Street’s top analyst calls
- Johnson & Johnson downgraded to Neutral from Outperform at Daiwa
- Johnson & Johnson seeks FDA approval of SPRAVATO
- Johnson & Johnson price target lowered to $155 from $160 at Goldman Sachs